What's Happening?
Orsini, a leader in rare disease pharmacy solutions, has announced its partnership with Glaukos to serve as the single-source specialty pharmacy partner for Epioxa, a novel treatment for keratoconus. Epioxa, which received FDA approval in October 2025,
offers a groundbreaking approach to corneal cross-linking, a procedure used to treat keratoconus, a progressive eye disease that thins the cornea and distorts vision. Unlike traditional methods, Epioxa is an incision-free, oxygen-enriched topical therapy activated by UV light, which does not require the removal of the corneal epithelium. This innovation aims to reduce pain, streamline the procedure, and minimize recovery time, providing significant benefits to patients and healthcare providers.
Why It's Important?
The introduction of Epioxa represents a significant advancement in the treatment of keratoconus, a condition that can lead to severe visual impairment and is a leading cause of corneal transplants in the U.S. By offering a less invasive and more efficient treatment option, Epioxa has the potential to improve patient outcomes and reduce the burden on the healthcare system. This partnership between Orsini and Glaukos highlights the importance of collaboration in bringing innovative therapies to market, particularly for rare diseases. The availability of Epioxa could lead to broader access to effective treatment for patients suffering from keratoconus, ultimately enhancing their quality of life.
What's Next?
As Orsini and Glaukos continue their partnership, the focus will likely be on expanding access to Epioxa and ensuring that patients and healthcare providers are informed about this new treatment option. Orsini's role as a specialty pharmacy partner will involve managing the distribution and patient services associated with Epioxa, ensuring that patients receive comprehensive support throughout their treatment journey. The success of this partnership could pave the way for further collaborations in the field of rare diseases, potentially leading to the development and distribution of additional innovative therapies.
